DSM Capital Partners Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Scientific
BSX
|
+$95.5M |
| 2 |
JD.com
JD
|
+$67.6M |
| 3 |
Automatic Data Processing
ADP
|
+$29.5M |
| 4 |
EPAM Systems
EPAM
|
+$26.2M |
| 5 |
Booking.com
BKNG
|
+$19.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MSCI
MSCI
|
+$110M |
| 2 |
Monster Beverage
MNST
|
+$60.4M |
| 3 |
Nice
NICE
|
+$3.6M |
| 4 |
Globant
GLOB
|
+$910K |
| 5 |
PagSeguro Digital
PAGS
|
+$851K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.82% |
| 2 | Consumer Discretionary | 19.84% |
| 3 | Communication Services | 15.37% |
| 4 | Healthcare | 14.19% |
| 5 | Financials | 12.45% |
Similar funds
DSM Capital Partners's Q4 2019 Portfolio in Review
As of Q4 2019, DSM Capital Partners held 53 positions worth $7.55B, up 16% from $6.5B the previous quarter. Its ten largest holdings account for 64% of the portfolio.
DSM Capital Partners deployed $245M of net new capital in Q4 2019, opening 2 new positions and adding to 36 existing holdings. Its largest new stake was Boston Scientific: 2,282,065 shares worth $103M.
By sector, the portfolio is most concentrated in Technology at 29% of assets, up from 28% a quarter earlier, followed by Consumer Discretionary and Communication Services.
On the sell side, the largest reduction was Monster Beverage, an estimated $60.4M trimmed.
- DSM Capital Partners's largest Q4 2019 buy was Boston Scientific: 2,282,065 shares worth $103M.
- DSM Capital Partners added most to JD.com in Q4 2019, an estimated $67.6M increase.
- DSM Capital Partners's biggest Q4 2019 reduction was Monster Beverage, cutting an estimated $60.4M.
- DSM Capital Partners fully exited MSCI in Q4 2019, selling an estimated $110M.
- DSM Capital Partners's ten largest holdings make up 64% of its $7.55B portfolio in Q4 2019.
- DSM Capital Partners opened 2 new positions and closed 5 in Q4 2019.
- DSM Capital Partners's portfolio value rose 16% quarter-over-quarter to $7.55B.
Based on DSM Capital Partners's 13F filing for Q4 2019, filed 13 Feb 2020.